Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strides’ Teriparatide And Viatris’ Pirfenidone Receive CHMP Nods

While AOP Orphan Pharmaceuticals Gets Positive Opinion For Sugammadex

Executive Summary

Strides Pharma’s biosimilar teriparatide version of Forsteo has been granted a positive opinion by the EMA’s CHMP, setting the firm up for a pan-European marketing authorization along with Viatris’ pirfenidone generic rival to Esbriet and AOP Orphan Pharmaceuticals’ sugammadex generic of Bridion.

You may also be interested in...



Sandoz US Pirfenidone Gamble Pays Off With Federal Circuit Victory

The US Court of Appeals for the Federal Circuit has comprehensively rejected Genentech’s patent-litigation appeal against Sandoz over the ANDA sponsor’s generic version of its Esbriet treatment for idiopathic pulmonary fibrosis.

Strides Begins Biosimilar Filings With Teriparatide

Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount

Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel